PTGX Protagonist Therapeutics, Inc.: Price-to-Projected Revenue Ratio
Should one expect an increase in the value of Protagonist Therapeutics (PTGX) due to patents for peptide developments for the immune system? The company's forward P/S provides the answer, where the 15.50 level captures the current state. Monopoly potential and inelastic demand for blood treatment confirm high future margins. The business's extreme scalability will ensure colossal revenue following regulatory approval of the drugs.
Analytical breakdowns for Protagonist Corp (PTGX)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Protagonist Therapeutics|PTGX - Company Aggregate Debts|Debts to Book Capitalization Protagonist Corp|PTGX - Long-Term Indebtedness|Company Short-Term Debt Protagonist Therapeutics|Quick Liquidity protagonist-inc.com
- business earnings and investment ratios data:
PTGX - Company Profit|Projected Future Earnings Protagonist Therapeutics|PTGX - Business Payback Period|Future Price to Earnings Protagonist Therapeutics Inc|PTGX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Protagonist Corp|PTGX - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Protagonist Therapeutics|PTGX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months protagonist-inc.com|PTGX - Net earnings per one share growth for the current year|Earnings growth forecast for next year Protagonist Therapeutics
- company sales and revenue statistics:
Fundamental company analysis:Protagonist PTGX
For a biotechnology sector investor, assessing whether an asset's valuation is inflated relative to expected cash flows is critical. In the case of Protagonist Therapeutics (PTGX), which focuses on clinical trials for immune drugs, the business's projected P/S ratio allows for a comparison of current market capitalization against expected revenue from future commercialization. This indicator measures the premium the market is willing to pay per unit of future sales, helping to identify safe entry points.
Main competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Future Price to Revenue ADMA|Immunovant, Inc. (IMVT) - Price-to-Projected Revenue Ratio|kiniksa.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Grifols|Market Cap to Future Revenue Ratio Adaptive Biotech ADPT|Forward Price-to-Revenue Multiple CLDX (Celldex)|Price to Expected Revenue Ratio AUPH|Forward P/S Multiple BCRX (BioCryst)|Forward P/S Multiple veratx.com VERA|Dianthus Therapeutics, Inc. - Forward P/S Multiple|Projected Price to Revenue Pharvaris NV (PHVS)|AbCellera Biologics Inc (ABCL) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tourmaline (TRML)|Price-to-Projected Revenue Ratio Precigen, Inc.|Market Cap to Projected Revenue PHAR (pharming.com)|Forward P/S Multiple NKTR|Market Cap to Expected Sales Ratio Upstream Bio, Inc.|Price-to-Projected Revenue Ratio Zenas Biopharma, Inc. ZBIO|Market Cap to Expected Sales Ratio Immunome Bio (IMNM)|GOSS: Forward Price-to-Revenue Multiple|kalvista.com - Price to Expected Revenue Ratio|SEPN (Septerna) - Forward Price-to-Revenue Multiple|Pieris Pharma - Forward Price to Sales|Forward Price-to-Revenue Multiple SVRA|RIGL (Rigel Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple ANAB|ATXS (astriatx.com) - Forward Price to Sales|Forward P/S Multiple ENGN (enGene)|RAPT Therapeutics Inc. (RAPT) - Market Cap to Future Revenue Ratio|JBIO - Price-to-Projected Revenue Ratio|Forward Price to Sales ACRS (Aclaris Therapeutics, Inc)|KYTX: Forward P/S Multiple|tizianalifesciences.com (TLSA) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Cabaletta Bio|Ventyx Biosciences Inc. - Future Price to Revenue|Forward P/S Multiple THTX|AVTX - Market Cap to Future Revenue Ratio|Eledon Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward P/S Multiple agenusbio.com AGEN|CLYM: Forward Price-to-Revenue Multiple|Zura Bio Ltd - Price to Expected Revenue Ratio|ATYR: Forward P/S Multiple|ADAG - Market Cap to Expected Sales Ratio|IMA (ImageneBio) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Shattuck Therapeutics (STTK)|Price-to-Projected Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Expected Sales Ratio connectbiopharm.com|Price-to-Projected Revenue Ratio Immunic IMUX|ATRA (Atara Biotherapeutics, Inc.) - Future Price to Revenue|IFRX: Forward Price-to-Revenue Multiple|x4pharma.com - Price to Expected Revenue Ratio|ACET: Forward P/S Multiple|Projected Price to Revenue Celularity CELU|Forward Price-to-Revenue Multiple INMB|Market Cap to Projected Revenue BRNS (Barinthus Biotherapeutics Corp)|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|SABS: Future Price to Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Forward Price to Sales ENLV|Q32 Bio Corp - Forward P/S Multiple|GOVX - Forward P/S Multiple|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|ibioinc.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Carisma Therapeutics Inc|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward P/S Multiple BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|Aptevo Therapeutics Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales AIM|Aditxt Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio GRI Bio Inc GRI|XORTX (XRTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Vyome Therapeutics|Price-to-Projected Revenue Ratio Revelation Biosciences|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|Forward P/S Multiple calcimedica.com (CALI)|Price-to-Projected Revenue Ratio Affimed N.V. AFMD|ALLK: Market Cap to Projected Revenue|HOOKIPA - Forward P/S Multiple|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Future Price to Revenue OCEA (Ocean Biomedical Inc)|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|THRD: Forward Price to Sales
